Glaxosmithkline | Beneficio Operativo



Operating Profit Cambio Fecha
AbbVie USD -1490000000 5.32B 2024-12
Amgen USD 2.31B 182M 2024-12
AstraZeneca USD 2.04B 731M 2024-12
Aurora Cannabis CAD 36.22M 38.61M 2024-12
Bausch Health Companies USD 318M 105M 2024-09
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Canopy Growth CAD -23822000 21.8M 2024-12
Corcept Therapeutics USD 25.26M 21.34M 2024-12
Drreddys Laboratories INR 18.72B 1.17B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
GlaxoSmithKline GBP 696M 507M 2024-12
Glaxosmithkline GBP 702M 513M 2024-12
Indivior 94M 226M 2024-09
J&J USD 3.89B 549M 2024-12
Merck USD 4.3B 369M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Pacira USD 24.7M 164.23M 2024-12
Perrigo USD 112.7M 37.4M 2024-12
Pfizer USD -409000000 5.57B 2024-12
Prestige Brands USD 91.96M 7.62M 2024-12
Roche Holding CHF 4.39B 1.04B 2024-12
Sanofi EUR 4.09B 1.81B 2024-09
Supernus Pharmaceuticals USD 21.4M 19.44M 2024-12
Takeda JPY 66.94B 117.3B 2024-12
Teva Pharmaceutical Industries USD 455M 506M 2024-12
Zoetis USD 732M 142M 2024-12



Glaxosmithkline Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.